Literature DB >> 30885765

Revisiting the combinatorial potential of cytokine subunits in the IL-12 family.

Sammy Detry1, Katarzyna Składanowska1, Marnik Vuylsteke2, Savvas N Savvides3, Yehudi Bloch4.   

Abstract

The four core members of the Interleukin-12 (IL-12) family of cytokines, IL-12, IL-23, IL-27 and IL-35 are heterodimers which share α- and β-cytokine subunits. All four cytokines are immune modulators and have been proposed to play divergent roles in inflammatory arthritis. In recent years additional combinations of α- and β-cytokine subunits belonging to the IL-12 family have been proposed to form novel cytokines such as IL-39. However, the actual extent of the combinatorial potential of the cytokine subunits in the human IL-12 family is not known. Here, we identify several combinations of subunits that form secreted heterodimeric assemblies based on a systematic orthogonal approach. The heterodimers are detected in the conditioned media harvested from mammalian cell cultures transfected with unfused pairs of cytokine subunits. While certain previously reported subunit combinations could not be recapitulated, our approach showed robustly that all four of the canonical members could be secreted. Furthermore, we provide evidence for the interaction between Cytokine Receptor Like Factor 1 (CRLF1) and Interleukin-12 subunit alpha (p35). Similar to IL-27 and IL-35 this novel heterodimer is not abundantly secreted rendering isolation from the conditioned medium very challenging, unlike IL-12 and IL-23. Our findings set the stage for fine-tuning approaches towards the biochemical reconstitution of IL-12 family cytokines for biochemical, cellular, and structural studies.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokines; Heterodimer; IL-12 family; Inflammation; Interleukin

Mesh:

Substances:

Year:  2019        PMID: 30885765     DOI: 10.1016/j.bcp.2019.03.026

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis.

Authors:  Javier Muñoz-Garcia; Denis Cochonneau; Stéphane Télétchéa; Emilie Moranton; Didier Lanoe; Régis Brion; Frédéric Lézot; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Lack of evidence for expression and function of IL-39 in human immune cells.

Authors:  Florence Ecoeur; Jessica Weiss; Simone Schleeger; Christine Guntermann
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

Review 3.  Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.

Authors:  Dennis McGonagle; Abdulla Watad; Kassem Sharif; Charlie Bridgewood
Journal:  Front Immunol       Date:  2021-03-19       Impact factor: 7.561

4.  Multifaceted Analysis of IL-23A- and/or EBI3-Including Cytokines Produced by Psoriatic Keratinocytes.

Authors:  Kota Tachibana; Nina Tang; Hitoshi Urakami; Ai Kajita; Mina Kobashi; Hayato Nomura; Minori Sasakura; Satoru Sugihara; Fan Jiang; Nahoko Tomonobu; Masakiyo Sakaguchi; Mamoru Ouchida; Shin Morizane
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

5.  Epigenetic DNA Methylation of EBI3 Modulates Human Interleukin-35 Formation via NFkB Signaling: A Promising Therapeutic Option in Ulcerative Colitis.

Authors:  Alexandra Wetzel; Bettina Scholtka; Fabian Schumacher; Harshadrai Rawel; Birte Geisendörfer; Burkhard Kleuser
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

Review 6.  IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions.

Authors:  Doreen M Floss; Jens M Moll; Jürgen Scheller
Journal:  Cells       Date:  2020-09-28       Impact factor: 6.600

Review 7.  A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions.

Authors:  Aruma Watanabe; Izuru Mizoguchi; Hideaki Hasegawa; Yasuhiro Katahira; Shinya Inoue; Eri Sakamoto; Yuma Furusaka; Ami Sekine; Satomi Miyakawa; Fumihiro Murakami; Mingli Xu; Toshihiko Yoneto; Takayuki Yoshimoto
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.